Overview of Surgical Approaches and Adjuvant Therapy for Treatment of Craniopharyngiomas
Clicks: 1
ID: 318502
2026
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This
article has not been analysed, so there is no overall score —
reader engagement is measured and shown alongside.
Reader Engagement
0.0
/100
1 views
0 readers
AI Quality Assessment
Not analyzed
Readership in this journal
Ranked #343 of 362 articles by views in the journal of clinical endocrinology & metabolism
Most read
Least read
Bar heights use a square-root scale. Only the 120 most-read articles are drawn; the journal has 362 in total.
Mint this article as an NFT
Not yet mintedCreate a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.
5
SUSD
one-off · no wallet required
Abstract
Craniopharyngiomas are brain tumors that occur in the sellar and suprasellar regions and are seen in both adult and pediatric patients. They are benign tumors, but their location and relation with critical neurovascular structures, including optic chiasm, hypothalamus, and pituitary gland, make their treatment challenging. Patients often present with headaches, neurologic symptoms, and pituitary dysfunction. Surgical resection is the first line of treatment. Historically, surgeries for these tumors involved open cranial approaches (OCA). However, endoscopic endonasal approaches (EEA) have become increasingly more popular in recent years. They provide similar to slightly increased rates of gross total resection and increased rates of visual preservation or improvement. Unfortunately, both options still carry significant risk of post-operative endocrinopathies for these patients. Given the involvement of these tumors with surrounding structures, especially the hypothalamus, current protocols recommend maximal safe resection followed by adjuvant therapies. Radiation therapy for tumor recurrences is often used. Intracystic therapies, including brachytherapy, bleomycin, and interferon alpha therapy, have all been tried with varying success. Lastly, advances in the understanding of molecular underpinnings of these tumors have led to promising new systemic therapies for certain subset of these tumors.
| Reference Key |
openalex_W7165660874
Use this key to autocite in the manuscript while using
SciMatic Manuscript Manager or Thesis Manager
|
|---|---|
| Authors | Nirali P Patel, Nathan Lu, Todd C. Hankinson |
| Journal | the journal of clinical endocrinology & metabolism |
| Year | 2026 |
| DOI |
10.1210/clinem/dgag242
|
| URL | |
| Keywords | Keywords not found |
Citations
No citations found. To add a citation, contact the admin at info@scimatic.org
Comments
No comments yet. Be the first to comment on this article.